p53 (139-147)
Need Assistance?
  • US & Canada:
    +
  • UK: +

p53 (139-147)

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

P53 has been described as ''the guardian of the genome'' because of its role in conserving stability by preventing genome mutation. Suppression of p53 in human breast cancer cells is shown to lead to increased CXCR5 chemokine receptor gene expression and activated cell migration in response to chemokine CXCL13.

Category
Others
Catalog number
BAT-009483
Synonyms
Cellular tumor antigen p53 (139-147); NY-CO-13 (139-147); Tumor suppressor p53 (139-147)
Sequence
KLCPVQLWV
Storage
Common storage 2-8°C, long time storage -20°C.
1. A HLA-A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitope
Peter A Würtzen, Mogens H Claesson Int J Cancer. 2002 Jun 1;99(4):568-72. doi: 10.1002/ijc.10375.
A p53 peptide-specific CTL line was generated through stimulation with autologous monocyte-derived dendritic cells (DC) pulsed with wild-type HLA-A2 binding p53 derived peptides. A p53 peptide-specific CD8(+) CTL line was established from a healthy HLA-A2 positive donor. The CTL line was characterized with respect to specificity, affinity and killing of cell lines derived from p53 mutated spontaneous tumors. The CTL line demonstrated lysis of p53(139-147) pulsed target cells and cold target inhibition experiments as well as antibody blocking confirmed that the killing was epitope-specific, HLA-A2 restricted and dependent on CD8-binding. Interestingly, the affinity of the CTL line was only in the micromole per liter range and target cells pulsed with less than 0.01 microM peptide were not recognized. Furthermore, 3 HLA-A2(+) p53 mutated tumor cell lines were efficiently lysed by the CTL line, indicating that this novel p53 peptide epitope is endogenously processed and presented by the HLA-A2 molecules of the tumor cells. In conclusion, CTL reactivity towards a wild-type p53 peptide was revealed through induction with DC pulsed with a pool of HLA-A2 binding p53 peptides. In addition, the CTL line, which expressed relatively low affinity for the HLA-A2/peptide complex, was able to kill 3 different HLA-A2(+) p53 mutated tumor cell lines. The present and our previous observations expand the number of p53-derived peptides suitable for vaccination protocols for cancer patients with p53 positive tumors.
2. Enhanced expression of aromatase in p53-inactivated mammary epithelial cells
Hoo Kyun Choi, Sang Hee Roh, Hyung Gyoun Kim, Eun Hee Han, Hye Gwang Jeong, Keon Wook Kang Endocr Relat Cancer. 2008 Mar;15(1):139-47. doi: 10.1677/ERC-07-0192.
Both the functional loss of p53 and the overexpression of aromatase are important for the progression of breast cancer in postmenopausal women. Here, we found that aromatase expression was up-regulated in primary cultures of mammary epithelial cells (p53(Delta)(5,6) MEC) isolated from mice with a defect in exons 5 and 6 of the p53 gene. Aromatase basal activity and expression levels were significantly increased in p53(Delta)(5,6) MEC when compared with wild-type MEC. Reporter gene activity in p53(Delta)(5,6) MEC transfected with the aromatase promoter or the cAMP-responsive element (CRE) minimal promoter was higher than wild-type MEC. p53 inactivation increased both Ser133-phosphorylated CRE-binding protein (CREB) and the nuclear accumulation of CREB. Inhibition of extracellular signal-regulated kinase (ERK) or Src tyrosine kinase blocked aromatase gene transactivation and CREB activation in the p53(Delta)(5,6) MEC. These results support the hypothesis that a genetic defect in the function of p53 enhances the expression of aromatase via ERK or Src activation in MEC, which suggests that aromatase expression is closely related to the p53 status in MEC.
3. Mechanisms of p53 degradation
Chuck C-K Chao Clin Chim Acta. 2015 Jan 1;438:139-47. doi: 10.1016/j.cca.2014.08.015. Epub 2014 Aug 27.
The tumor suppressor p53 plays various functional roles in the cell by regulating multiple regulatory signals that ensure adequate temporal and spatial responses to cellular stress. p53 is usually kept inactive due to ubiquitination by a number of E3 ubiquitin ligases that target p53 for proteasomal degradation. The ubiquitously expressed proto-oncogene Mdm2 is the major E3 ubiquitin ligase involved in this process and is critical for regulating p53 homeostasis. Ubiquitination by E3 ligases may induce cellular relocation of p53 and determine the outcome of p53-mediated stress response, including cell proliferation, apoptosis and efficacy of cancer therapy. In addition to marking p53 for proteasomal degradation, ubiquitination acts as a signal for the degradation-independent functions of p53, such as nuclear export and transcriptional activation. Importantly, the reversible nature of the ubiquitination process and the identification of de-ubiquitination enzymes acting on p53 have added yet another layer of regulatory mechanism controlling p53 activity. This review highlights our current understanding of the mechanisms underlying p53 degradation as well as the significance of the p53 pathway in response to genotoxic stress.
Online Inquiry
Verification code
Inquiry Basket